Moderna Advances Cancer Pipeline with mRNA-4106 Immunotherapy Trial in Solid Tumors
Key Insights
Moderna is conducting a Phase 1 dose-escalation study of mRNA-4106 (search), an mRNA-based immunotherapy designed to help the immune system recognize and attack cancer (search) cells in patients with advanced solid tumors (search).
The trial tests mRNA-4106 (search) both as a standalone treatment and in combination with nivolumab/relatlimab immunotherapy to evaluate safety and tolerability in this early-stage study.
This oncology program represents Moderna's strategic expansion beyond COVID-19 vaccines into cancer (search) treatment, marking a key component of the company's long-term growth diversification strategy.
Moderna has initiated a Phase 1 clinical trial for mRNA-4106 (search), an investigational mRNA-based immunotherapy targeting solid tumors (search), as the company continues its strategic expansion into oncology beyond its established COVID-19 vaccine franchise.
Novel mRNA Cancer Immunotherapy Approach
The study, titled "A Phase 1, Open-label, Multicenter, Dose-escalation Study of mRNA-4106 (search) Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (search)," aims to evaluate the safety and tolerability of mRNA-4106 in patients with advanced solid tumors. The investigational therapy utilizes mRNA technology to enhance the immune system's ability to recognize and attack cancer (search) cells.
mRNA-4106 (search) is administered as an intramuscular injection and is being tested both as a monotherapy and in combination with nivolumab/relatlimab, an approved immunotherapy delivered via intravenous infusion. The combination approach seeks to determine whether the dual treatment can enhance anti-tumor activity while maintaining an acceptable safety profile.
Study Design and Timeline
The Phase 1 trial employs a non-randomized, sequential design where participants are assigned to predetermined treatment groups rather than through randomization. As an open-label study, both investigators and patients are aware of which treatment is being administered. The dose-escalation methodology allows researchers to systematically increase dosing levels to identify the optimal therapeutic window.
The study was first submitted in March 2025, marking Moderna's formal entry of this oncology program into clinical development. The most recent protocol update was filed on April 30, 2025, with the trial currently in active recruitment phase. As typical for Phase 1 trials, primary and final completion dates extend several years into the future, with safety readouts and initial clinical activity signals expected as enrollment progresses.
Strategic Diversification Beyond COVID-19
This oncology initiative represents a critical component of Moderna's broader strategy to diversify its pipeline and reduce dependence on COVID-19 vaccine revenue. The company's expansion into cancer (search) immunotherapy aligns with the established immuno-oncology ecosystem, particularly through its combination approach with Bristol Myers Squibb (search)'s nivolumab/relatlimab product.
The Phase 1 study's primary focus remains on safety assessment rather than efficacy demonstration, which is standard for early-stage oncology trials. Positive safety data and preliminary activity signals from mRNA-4106 (search) could strengthen investor confidence in Moderna's oncology platform and support the company's long-term growth trajectory, though Phase 1 results typically have limited immediate market impact.
The trial continues active recruitment, with detailed protocol information available through the ClinicalTrials.gov portal, as Moderna executes on its cancer (search) treatment strategy and expands its clinical development portfolio beyond infectious disease applications.